Wyeth

CompanyUnited States

Wyeth develops one asset, in phase 3 (sirolimus in aged). Mostly small molecule acting on autophagy, mTOR signalling and MTOR; based in the United States.

1
Asset
Furthest: Phase 3; 39
Trials: 0
Signals

Pipeline

1

sirolimus
mTOR inhibitor delivered perivascularly via a collagen implant to improve arteriovenous fistula maturation.
Phase 3, Small molecule, Autophagy, mTOR signalling, aged, aging

Full company profiles: pipeline, trials, funding and people.

In the full profile

Evidence behind the mechanisms6
Trials62
Signals4
Similar companies6

Updated 9 Oct 2026 · 114 sources